Informing the selection of futility stopping thresholds: Case study from a late-phase clinical trial

Pharmaceutical Statistics

Volumn 8, Issue 1, 2009, Pages 25-37

  Hughes, Sara ^a   Cuffe, Robert L ^a   Lieftucht, Alfons ^a   Nichols, W Garrett ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Conditional power; Decision analysis; Futility; Group sequential; Stopping rule

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

CASE STUDY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; POWER ANALYSIS; RESEARCH PRIORITY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ARTICLE; DECISION SUPPORT SYSTEM; ETHICS; METHODOLOGY; STATISTICS; THEORETICAL MODEL;

CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; HUMANS; MODELS, THEORETICAL; RESEARCH DESIGN; RISK ASSESSMENT; STATISTICS AS TOPIC;

EID: 65649083667     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.323     Document Type: Review

References (21)

1. Gazzard B on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine 2006; 7:487-503.
2. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel Report, Panel on clinical practices for treatment of HIV infection, October 2006.
3. Eron Jr J, Yeni P, Gathe Jr J et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. The Lancet 2006; 368(9534):476-482.
4. Palella F, Delaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 1998; 338:853-860.
5. Bergersen BM. Cardiovascular risk in patients with HIV infection: impact of antiretroviral therapy. Drugs 2006; 66:1971-1987.
6. Friis-Møller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. The New England Journal of Medicine 2003; 349:1993-2003.
7. Law MG, Friis-Møller N, El-Sadr WM et al. The use of the framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Medicine 2006; 7: 218-230.
8. Ruane P, Luber A, Wire MB. Plasma amprenavir (APV) pharmacokinetics (PK) and safety following co-administration of fosamprenavir (Lexiva) with a reduced ritonavir (RTV) dose once-daily QD (COL10053). Antimicrobial Agents and Chemotherapy 2006; AAC.00560-06v1.
9. Smith K, Weinberg W, DeJesus E et al. Once-daily fosamprenavir or atazanavir, both boosted by ritonavir 100 mg, plus tenofovir/ emtricitabine combination tablet: a planned week 24 interim analysis of the ALERT study. Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12 November-16 November 2006; Abstract P1.
10. Hicks C, DeJesus E, Sloan L et al. Once daily fosamprenavir (FPV) with a reduced dose of ritonavir (RTV), given with abacavir (ABC)/ lamivudine (3TC) combination tablet: a planned week 24 interim analysis of the REDUCE study. Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12 November-16 November 2006; Abstract P2.
11. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of non-inferiority trials. Annals of Internal Medicine 2006; 145:62-69.
12. Cui Y, Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Archives of Internal Medicine 2001; 161:1413-1419.
13. Snapinn S, Chen M-G, Jiang Q, Koutsoukos T. Assessment of futility in clinical trials. Pharmaceutical Statistics 2006; 5:273-281.
14. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Chapman & Hall/CRC: London, Boca Raton, FL, 2000.
15. Halperin M, Lan KKG, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in longterm clinical trials. Controlled Clinical Trials 1982; 3(4):311-406.
16. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988; 44:579-585.
17. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 1986; 7:8-17.
18. Davis BR, Hardy RJ. Repeated confidence intervals and predictions using stochastic curtailing. Communications in Statistics - Theory and Methods 1992; 21:351-368.
19. Lachin JM. A review of methods for futility stopping based on conditional power. Statistics in Medicine 2005; 24:2747-2764.
20. Whitehead J, Matsushita T. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Statistics in Medicine 2003; 22:677-687.
21. Van der Tweel I, Van Noord PAH. Early stopping in clinical trials and epidemiologic studies for 'futility': conditional power versus sequential analysis. Journal of Clinical Epidemiology 2003; 56: 610-617.